TSP Capital Management Group LLC Grows Stock Holdings in Novavax, Inc. $NVAX

TSP Capital Management Group LLC raised its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 3.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,399,065 shares of the biopharmaceutical company’s stock after purchasing an additional 46,900 shares during the quarter. Novavax accounts for about 2.8% of TSP Capital Management Group LLC’s portfolio, making the stock its 17th largest position. TSP Capital Management Group LLC owned about 0.86% of Novavax worth $8,814,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in NVAX. SBI Securities Co. Ltd. raised its position in shares of Novavax by 5.5% during the 2nd quarter. SBI Securities Co. Ltd. now owns 34,095 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 1,766 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Novavax by 2.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 2,750 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Novavax by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,169 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 2,780 shares during the last quarter. Signaturefd LLC raised its position in Novavax by 47.2% during the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 3,122 shares during the period. Finally, Monaco Asset Management SAM raised its position in Novavax by 1.8% during the first quarter. Monaco Asset Management SAM now owns 290,000 shares of the biopharmaceutical company’s stock valued at $1,859,000 after purchasing an additional 5,000 shares during the period. 53.04% of the stock is currently owned by institutional investors.

Novavax Trading Down 3.4%

NVAX stock opened at $6.57 on Wednesday. Novavax, Inc. has a 12 month low of $5.01 and a 12 month high of $11.55. The firm’s 50-day moving average is $8.30 and its 200 day moving average is $7.60. The company has a market capitalization of $1.07 billion, a PE ratio of 2.88, a P/E/G ratio of 0.12 and a beta of 2.68. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The company had revenue of $70.45 million for the quarter, compared to analysts’ expectations of $55.63 million. During the same period last year, the business posted ($0.76) earnings per share. The business’s revenue was down 16.7% compared to the same quarter last year. Novavax has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Analysts Set New Price Targets

NVAX has been the subject of a number of analyst reports. TD Cowen lowered their price target on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. Bank of America reaffirmed an “underperform” rating and set a $7.00 price target (down from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. Cantor Fitzgerald initiated coverage on shares of Novavax in a research note on Friday, October 24th. They issued an “overweight” rating and a $18.00 price objective for the company. Wall Street Zen lowered Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a research note on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Novavax has a consensus rating of “Hold” and an average target price of $11.25.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.